Amira Pharmaceuticals and GSK, global agreement for FLAP inhibitor programme

4-February-2008: Amira Pharmaceuticals and GlaxoSmithKline enter global agreement for FLAP inhibitor program. Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory diseaseAmira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein¬) inhibitors for the treatment of respiratory and cardiovascular disease... Amira Pharmaceuticals' Press Release - GlaxoSmithKline's Press Release -

Amira Pharmaceuticals, Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease

November 1, 2007 - ...AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production... Amira 's Press Release -